Bispecific Antibodies: A Playbook for Relapsed/Refractory Follicular Lymphoma - report from ASH2024
Joshua Brody, MD discusses the advancing field of bispecific antibodies in third-line relapsed/refractory follicular lymphoma.
Video: https://medicaldigest.org/scientific-contents/interview:bispecific-antibodies-playbook-relapsedrefractory-follicular-lymphoma
S12 Ep3: Clinical Practice Insights Reveal the Complexity of Lymphoma Subtypes and Advances in First-Line Treatments: With Chandler Park, MD; and Joshua Brody, MD
In this Oncology Unplugged discussion, Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, and Joshua Brody, MD, director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai in New York, New York, explored the heterogeneity of l…
What is the clinical significance of the long-term results from the EPCORE NHL-2 trial of epcoritamab + R-CHOP for previously untreated high-risk DLBCL?
During the 18th International Conference on Malignant Lymphomas (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US. We asked about the clinical significance of the long-term results from the EPC…
Novelties in Follicular Lymphoma at ASH2025
Joshua Brody discusses the novelties in follicular lymphoma at the American Society of Hematology's 67th Annual Meeting.
Video: https://medicaldigest.org/scientific-contents/interview:novelties-follicular-lymphoma-ash2025
Novelties in Diffuse Large B-cell Lymphoma at ASH2025
Joshua Brody discusses the novelties in diffuse large B-cell lymphoma at the American Society of Hematology's 67th Annual Meeting.
Video: https://medicaldigest.org/scientific-contents/interview:novelties-diffuse-large-b-cell-lymphoma-ash2025
ASH 2025 | Key highlights in lymphoma and CLL
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US. Brody discussed the key highlights in lymphoma and chronic lym…
Annual oncology meeting | Key highlights in lymphoma
During the American Society of Clinical Oncology Annual Meeting, May 19 – June 2, 2026, Chicago, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US.
Hosted on Acast. See acast.com/privacy for more information.
S18 Ep36: Precision Immunotherapy, PET-Adapted Regimens, and Novel Targets Are Redefining Hodgkin Lymphoma Care: With Chandler Park, MD; Joshua Brody, MD
In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Joshua Brody, MD, the director of the Lymphoma Immunotherapy Program at the Mount Sinai Tisch Cancer Center and a faculty member of the Icahn Genom…
S18 Ep38: Fast-Moving Treatment Advances Shape B-Cell Lymphoma Care
In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Joshua Brody, MD, the director of the Lymphoma Immunotherapy Program at the Mount Sinai Tisch Cancer Center and a faculty member of the Icahn Genom…
Optimizing the Outcomes for Diffuse Large B-cell Lymphoma in the Community
Host: Joshua Brody, MD, Icahn School of Medicine at Mount SinaiGuest: Jeremy Abramson, MD, MMSC, Harvard Medical School
This episode is supported by an educational grant from Genentech.
Episode Summary:Until recently, patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who co…
محرك بحث البودكاست
يمكنك استخدام موقعنا الإلكتروني للبحث في ملفات podcast3,831,901وحلقات196,888,410حسب الأشخاص أو الأماكن أو المواضيع.
I have no special talent. I am only passionately curious, and
I listen to podcasts.
‐ Albert "Llamacorn" Einstein
تعديل
شكراً على مساعدتنا في الحفاظ على قاعدة بيانات البودكاست مُحدَّثة.
